Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
560 participants
INTERVENTIONAL
2003-06-30
2005-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)
NCT00866294
MDD POC Study GSK372475 Subjects Depressive Disease
NCT00420641
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
NCT00048204
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
NCT01670279
A Local Register Study For Major Depression Of Paroxetine Controlled Release
NCT00368303
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Paroxetine CR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current major depressive episode at screen at least 2 months duration.
* Must be at least 60 years of age.
Exclusion Criteria
* Patients with a history of schizophrenia, schizoaffective disorder, bipolar disorder or dementia.
* Patients with a history of brief depressive episodes lasting less than 8 weeks.
* Patients receiving formal psychotherapy within 12 weeks of study.
* Patients who are suicidal.
* Patients who have received electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior to screening.
* Patients with a history or seizure disorders.
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Anaheim, California, United States
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
El Centro, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Redlands, California, United States
GSK Investigational Site
Santa Ana, California, United States
GSK Investigational Site
Colorado Springs, Colorado, United States
GSK Investigational Site
Norwich, Connecticut, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Leesburg, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Sebring, Florida, United States
GSK Investigational Site
St. Petersburg, Florida, United States
GSK Investigational Site
West Palm Beach, Florida, United States
GSK Investigational Site
Marietta, Georgia, United States
GSK Investigational Site
Boise, Idaho, United States
GSK Investigational Site
Lafayette, Indiana, United States
GSK Investigational Site
Overland Park, Kansas, United States
GSK Investigational Site
Prairie Village, Kansas, United States
GSK Investigational Site
Gaithersburg, Maryland, United States
GSK Investigational Site
Rockville, Maryland, United States
GSK Investigational Site
Braintree, Massachusetts, United States
GSK Investigational Site
Nashua, New Hampshire, United States
GSK Investigational Site
Clementon, New Jersey, United States
GSK Investigational Site
Princeton, New Jersey, United States
GSK Investigational Site
Mount Kisco, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Greensboro, North Carolina, United States
GSK Investigational Site
Raleigh, North Carolina, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Eugene, Oregon, United States
GSK Investigational Site
Conshohocken, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
East Providence, Rhode Island, United States
GSK Investigational Site
Charleston, South Carolina, United States
GSK Investigational Site
Memphis, Tennessee, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pitts CD, Schaefer D, Lipschitz A, Iyengar M: Efficacy and Tolerability of Fixed, Low Dose Paroxetine CR in the Treatment of Depression in the Elderly, Poster No. NR701, presented at the American Psychiatric Association Annual Meeting, May 2005. Available at: www.psych.org
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Statistical Analysis Plan
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
29060/874
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.